William Facteau is the Vice Chairman of ExploraMed Development, LLC, a medical device incubator based on the West Coast. In addition he serves as an Entrepreneur in Residence with New Enterprise Associates. He also serves as the Chairman of the Board for Cabochon Aesthetics, Inc. and sits on the Board of Directors of ExploraMed Development LLC, NeoTract, Inc., Automatic Technologies (ATI), Earlens Corporation, and formerly CV Ingenuity (CVI), Inc., which was acquired by Covidien in 2013.
Prior to this, Mr. Facteau joined Johnson and Johnson in January 2010 after Ethicon acquired Acclarent for $785 million in cash where he served as the Worldwide President of Acclarent, a dedicated stand-alone ENT division of Ethicon. Prior to the acquisition, Mr. Facteau joined Acclarent and its founders in 2004 as the President, CEO, and a member of the Board of Directors. Under Facteau’s leadership, the company went from concept to acquisition in 5 ½ years, raised over $100M, created jobs for approximately 400 employees, grew revenues to $100M and became profitable. Prior to joining Acclarent, Mr. Facteau was the General Manager of the Endovascular Division at Abbott Vascular, where he served as a member of the executive team and created the entry strategy for Abbott to participate in the peripheral vascular space. Mr. Facteau joined Abbott Laboratories via the $683 million acquisition of Perclose, a vessel closure company, where he was the Area Sales Director. From July 1993 to April 1998, Mr. Facteau worked in a number of sales and sales management positions at United States Surgical Corporation. Mr. Facteau received his B.A. in Political Science from the University of Connecticut, and is a named inventor on several issued patents.